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Cervical cancer remains the leading cause of death by gynecologic cancer worldwide, comprising 15% of all cancers in 
women younger than 40 years. Standard treatments of invasive cancer in early stages are radical hysterectomy and 
pelvic radiotherapy, both of which are almost reliable by minimal invasive surgery, so as traditional laparoscopy and 
robotic-assisted surgery. Moreover, 45% of reproductive-age women are diagnosed with stage IB1 disease, making the 
fertility-sparing procedure, radical trachelectomy, a viable option for most patients for treatment of early-stage cervical 
cancer and maintenance of future fertility.  
This chapter focuses on emerging surgical techniques, including the laparoscopic and robotic approach, are improving 
perioperative outcomes for these patients. 
A manual and computer-aided search was carried out for all reviews related to this topic, randomized controlled trials, 
prospective observational studies, retrospective studies and case reports published between 1980 and 2012, assessing 
robotic surgery, Search strings were: laparoscopic surgery; robot or robot-assisted surgery; radical hysterectomy; cervical 
cancer, minimally invasive surgery.  
Robotic-assisted gynecologic surgery has increased worldwide, considering the number of scientific articles dedicated to 
it though few retrospective and prospective studies have demonstrated the feasibility of robotic-assisted surgery in 
radical hysterectomy. In general, robot-assisted gynecologic surgery is often associated with longer operating room time 
but generally similar clinical outcomes, decreased blood loss, and shorter hospital stay. Robotic-assisted procedures are 
not, however, without their limitations: the equipment is still very large, bulky, and expensive, the staff must be trained, 
specifically on draping and docking the apparatus to maintain efficient operative times. Functional limitations include 
lack of haptic feedback, limited vaginal access, limited instrumentation, and larger port incisions. Exchanging 
instruments becomes more cumbersome and requires a surgical assistant to change the instruments. Additionally, the 
current robotic instruments do not include endoscopic staplers or vessel sealing devices. Finally, laparoscopic radical 
hysterectomy is a feasible and safe procedure that is associated with fewer intraoperative and postoperative 
complications than abdominal radical hysterectomy. The role of robotic-assisted surgery is continuing to expand, but 
well-designed, prospective studies with well-defined clinical, long-term outcomes, including complications, cost, pain, 
return to normal activity, and quality of life, are needed to fully assess the value of this new technology in radical 
hysterectomy. 
Scientific literature has shown the feasibility of a radical resection by minimally invasive oncological surgery and 
documented an equivalent number of pelvic nodes harvested by laparoscopy and open surgery.  
Women with a tumor size 2 cm or smaller and stage IA1 with lymphovascular space involvement (LVSI), IA2, or IB1 
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Introduction 
Cervical cancer is the second most common cancer in women worldwide and is a leading cause of cancer-related death 
in women in underdeveloped countries. Worldwide, approximately 500,000 cases of cervical cancer are diagnosed each 
year: approximately 13,000 cases of invasive cervical cancer and in the USA 50,000 cases of cervical carcinoma in situ 
(i.e., localized cancer) are diagnosed yearly. In developed countries, over the last 40 years, cervical cancer death rate has 
decreased by more than 70% because pre-invasive lesions and cervical cancers were detected at an earlier stage [121]. 
Cervical cancer is always associated with a HPV infection, since a carcinogenic human papillomavirus (HPV) infection is 
necessary for the development of cervical cancer [122].  
Cervical cancer risk seems to be influenced by other variables too, like smoking and immunodeficiency. Infection with 
other sexually transmitted viruses seems to act as a cofactor in the development of cervical cancer [120]. 
We will focus on fertility-sparing techniques such as radical trachelectomy and on the area of minimally invasive 
treatment of cervical cancer, since this tumor can be safely and feasibly managed from minimally invasive endoscopic 
radical operations, such as hysterectomy, bilateral salpingo-oophorectomy, pelvic and para-aortic lymphadenectomy for 
surgical treatment. 
 
Cervical cancer staging and radical hysterectomy classification 
Correct staging of advanced cervical cancer is essential to optimize its oncological treatment. However, the new FIGO 
classification is limited to clinical findings and does not include complex imaging. The rationale is to provide a template 
allowing both resource-rich and resource-poor countries to compare data by stage so as to standardize management of 
the disease.  
It can be difficult to accurately assess parametrial and sidewall invasion, as well as metastases to lymph nodes, using 
clinical staging alone. These are the limitations of FIGO clinical staging. 
The purpose of the staging system is to provide uniform terminology for better communication among health 
professionals and to provide appropriate prognosis for the patients resulting in treatment improvement. [84]. 
This is a constantly evolving process as new therapeutic modalities are being developed and new imaging and surgical 
approaches are applied. In those countries where medical research and more prognostic information has become 
available, in recent years, new knowledge has boomed.  
A constantly evolving process is also being applied in surgery techniques. The term “radical” or “extended” 
hysterectomy encompasses various types of surgery. Since the first publications of large series of surgeries for cervical 
cancer by Wertheim in Austria [129] and later by Okabayashi in Japan [80] and Meigs in the USA [72], many radical 
procedures according with different degrees of radicality have been described and performed.  
The problem with all these procedures is that they name the same anatomical structures differently and define these 
structures according to different anatomic interpretations. 
In this scenario, the Piver–Rutledge–Smith classification published in 1974 has achieved substantial popularity. [88]. It 
describes five classes of radical hysterectomy [119] including a class I category, which is not radical hysterectomy, and a 
class V category, which is no longer used. The rationale and anatomic definitions for differentiation between class III and 
IV are unclear. Surgeons frequently need to define intermediate classes inbetween classes II and III (eg, II-III or II-and-a-
half). The original paper does not refer to clear anatomical landmarks or international anatomical definitions. The 
vaginal extent of resection is systematically attached to the pericervical extent; vaginal resection is excessive—from a 
third to three-quarters of the vagina.  
The classification by Piver and colleagues [88] does not take into account the idea of nerve preservation that was 
introduced in the 1950s [46] and subsequently refined by Japanese surgeons [33,108] and adopted by European surgeons 
[105,123]. 
The Piver–Rutledge–Smith classification applies to open surgery only. 
Querleu and Morrow recently published a new radical hysterectomy classification, based, for simplification’s sake, on 
only the lateral extent of uterine resection [98]. 
Only four types of radical hysterectomy are described, adding a few subtypes when necessary. Instead of the 
classification by Piver and colleagues, stable anatomical landmarks are used to define the limits of resection. To make a 
clear distinction with the Piver–Rutledge–Smith [88], in the Querleu and Morrow classification [98] letters are used 
rather than numbers to define classes. 
Simple hysterectomy is not included in the classification. Lymph-node dissection, an essential part of surgical cervical 
cancer management, is considered separately. 
For lymph-node dissections, the limit between level 1 and level 2 is the bifurcation of the common iliac artery; the limit 
between level 2 and level 3 the bifurcation of the aorta; and the limit between level 3 and level 4 the inferior mesenteric 
artery. 
 
History and evolution of surgery in cervical cancer 
The ancient Egyptians used bamboo knives and in ancient India volcanic glass, obsidian, was used to operate on 
patients. Over 1,000 years later until now, steel scalpels have been used to perform surgery. Only 200 years ago, in 1809, 
the first documented laparotomy was performed for a gynaecological tumour by Ephraim McDowell, who removed an 
ovarian cyst. 
Since the late nineteenth century until now, surgery, and in particular radical surgery, has taken an astonishingly 
conservative approach. The same technique for radical cervical surgery surgery as introduced by Ernst Wertheim in 1896 
[129] is still being used today, and gynaecological oncological surgeons are very reluctant to change even minor details 
of this operation. Essentially, radical gynaecological surgery has remained fairly standard and unchanged. 
Although a first attempt at laparoscopy, on his dog, was made by Georg Kelling in 1901, it took until the 1970s for 
laparoscopy to be introduced into gynaecological surgery. In the beginning, it was only used for diagnostic purposes and 
sterilizations. As recently as 1989, the first series of ‘laparoscopically assisted vaginal hysterectomy’ were reported by 
Harry Reich [106].  
Two years earlier, Daniel Dargent [23] had described the use of laparoscopy as ‘presurgical retroperitoneal pelviscopy 
for Schauta’s operation’ in preparation for the vaginal approach for cervical cancer . In 1992, Camran Nezhat [74] 
performed the first laparoscopic radical hysterectomy with pelvic and para-aortic lymph node dissection.  
In 2000, Dargent et al. reported successful laparoscopic vaginal radical trachelectomy and pelvic lymphadenectomy for 
young women with cervical cancer, who wanted to preserve their fertility [22].  
In 2000, Possover et al. reported modified laparoscopic nerve sparing type III radical hysterectomy for cervical cancer 
and found that this procedure decreased postoperative bladder dysfunction incidence [94] subsequently Pomel et al. 
evaluated, in a series of 50 consecutive patients, the feasibility, morbidity, and survival outcome of laparoscopic radical 
hysterectomy for carcinoma of the uterine cervix [90]. 
With technical advances and emerging devices, as well as accumulating experience in laparoscopic surgery, some 
surgical procedures that are difficult to carry out even by traditional open procedures can be performed successfully by 
laparoscopy. 
The major advantages associated with minimally invasive laparoscopy are, amongst others, lower intraoperative 
bleeding rates, less post-operative pain, a shorter recovery time and a shorter hospital stay.  
In addition, the optical devices used for laparoscopic surgery feature a 10 to 15 times magnification and, therefore, 
provide an excellent view of pelvis anatomy.  
During the past decade some reports, on a limited number of patients, have shown the feasibility of radical resection by 
laparoscopic surgery and have documented an equivalent number of pelvic nodes harvested by laparoscopy and open 
surgery [11,38,42,49,91, 112,118]. 
Nevertheless, few long-term data on the morbidity and survival after laparoscopic radical hysterectomy are available. 
In gynecological oncology laparoscopic surgery does not substantially reduce tissue trauma, which makes it possible for 
extensive and complex operative procedures to be performed through small incisions, reducing intra-operative blood 
loss and impact on the body as well as common surgical complications. In addition, laparoscopic surgery is superior to 
conventional surgery with regard to postoperative mental rehabilitation in gynecological oncology patients.  
From the original publications on this radical hysterectomy surgery, surgical technique has aimed at a re-classification 
including a variety of techniques via laparotomy [3,64], then via laparoscopy, resulting in reasonable morbidity with 
similar surgical outcomes [1,66]. 
However, longer operating times, steep learning curves, and lack of training have prevented laparoscopic treatment 
from becoming a widely adopted surgical approach to radical hysterectomy [7,104]  
Although open radical hysterectomy is still considered the gold standard for the treatment of early cervical cancer [2], 
laparoscopic radical (LRH) and laparoscopy-assisted radical vaginal hysterectomy (LARH) are evolving as potential 
surgical alternatives. 
The principles are: to resect tumor and its surrounding tissues en bloc, to use tumor-free techniques when manipulating 
tumors, to preserve sufficiently incised margins, and to perform complete pelvic lymphadenectomy. Lymph node status 
is the most important prognostic factor in gynecologic tumor and surgical removal of the pelvic. Para-aortic lymph 
nodes for histological assessment is part of gynecologic malignancies staging.  
Hence, laparoscopic surgery is consistent with the concept of minimally invasive surgery, i.e., smaller trauma, milder 
pain or analgesia, better homeostasis, more accurate operative outcomes, shorter hospital stay and better psychological 
effects than current standard open surgery. As a technical innovation, laparoscopic techniques for gynecological 
oncology do not change gynecological oncological surgery fundamentally, but they have improved surgical techniques 
for gynecological oncology in many aspects, and enhanced the efficacy of surgical cervical cancer treatment. 
Additionally, removal of bulky lymph nodes may have therapeutic benefit. According to the requirement by established 
FIGO classification systems, a different range of lymphadenectomy will be performed depending on the different type of 
tumor present. The range of lymphadenectomy, consistent with that of open abdominal surgery, depends on cervical 
cancer disease. Lymph nodes, para-aortic and iliac vessels are resected within the vessel sheath. Obturator and deep 
inguinal lymph nodes, including lymph nodes below the obturator nerve, must be resected radically. 
The indication for laparoscopic surgery was similar to open surgery in cervical cancer patients.  
According to literature and our experience, the indication for laparoscopic radical hysterectomy (type III) and pelvic 
lymphadenectomy was earlier than the FIGO stage IIa in cervical cancer [68].  
The indication for this surgical procedure is mainly influenced by the experience of the surgeon [57]. 
More recently, it was reported that stage IIb or more advanced cervical cancer may be treated with type IV radical 
hysterectomy under laparoscopy [16, 92, 98], as the aim of surgery is to stage and radically resect the tumor (including 
metastases). For certain patients, prolong survival is the objective of tumor treatment. 
 
Laparoscopic and robotic-assisted approaches in gynaecological malignancies 
The goal of laparoscopic surgery is to duplicate traditional open procedures via small incisions in the skin with surgical 
outcomes equivalent or superior to a traditional surgical approach. 
Laparoscopy offers multiple advantages in the management of malignancy, including smaller incisions, shorter hospital 
stay, quicker recovery, improved visualization, less need for postoperative analgesics, and a lower risk of complications, 
such as blood loss, wound infection, herniation, and ileus.  
These characteristics may prove particularly important in the setting of oncology where a shorter recovery period may 
facilitate a shorter interval to postoperative treatments such as chemotherapy or radiation. Laparoscopy also has its 
limitations.  
Disadvantages include a long learning curve, counterintuitive motions, and limited depth perception as imaging is 
limited to 2-dimensional views. 
In an effort to overcome these limitations, multiple innovations have evolved over the last decade. Laparoscopic 
instrumentation has expanded to include several different vessel sealing devices with integrated cutting capabilities, 
endoscopic staplers, articulating instrument tips, 3-dimensional capabilities, and computer-enhanced technology in the 
form of robotics. 
Therefore, robotic surgical systems seem to be the future in gynecologic surgery, since robotic technology can improve 
accuracy, enhance dexterity, and provide for faster suturing and a lower training curve than laparoscopy.  
All of this makes gynecologic surgeons tend to perform a greater number of gynecologic procedures by robotic 
approach, when available. In the last five years, a large number of robotic surgery related papers have been published, 
both for benign and oncological cases, which is proof of the rapid spread and high acceptance of this new technology. 
Gynecological oncology probably presents the optimal forum for application of robotics, given the complexity of surgical 
steps involved in performing radical hysterectomies for cervical cancer and lymph node sampling for endometrial 
cancer.  
Radical hysterectomy was one of the first indications for robot-assisted laparoscopy, as this made it possible to perform a 
complex and long procedure laparoscopically. Studies comparing the results of robot-assisted and conventional 
laparoscopic surgery yielded slightly different but conflicting results. Boggess et al. [5] found a rate of 7.8 % for major 
complications after robotic surgery, compared with 16.3 % after conventional laparoscopic surgery, whereas 
Kruidenberg et al. [51] found just the opposite, with 9.6 % and 5.5 %, respectively (statistically significant differences in 
both studies). Survival after both modalities seems to be similar. 
 
The history of laparoscopy in cervical cancer 
In 1989, Querleu et al. [97] performed the first laparoscopic pelvic lymphadenectomy for cervical cancer, then, in 1990, 
Canis et al. described a totally laparoscopic radical hysterectomy [12]. In 1991, Querleu et al. reported laparoscopic pelvic 
lymphadenectomy and vaginal assistant radical hysterectomy for early cervical cancer [100].  
In 1992 and in 1993, Nezhat et al. reported the first case of cervical cancer treated with laparoscopic radical hysterectomy 
and pelvic lymphadenectomy [74,75]. 
Since then, the techniques have been applied clinically and achieved satisfactory clinical outcomes [36], Vaginal radical 
trachelectomy and laparoscopic pelvic lymphadenectomy were done by Dargent et al. [22]. 
In 2000, Possover et al. reported modified laparoscopic nerve sparing type III radical hysterectomy for the treatment of 
cervical cancer, and found that this procedure decreased the incidence of postoperative bladder dysfunction [60]. 
In 2003, Pomel et al. reportedthe feasibility, morbidity, and survival outcome of the laparoscopic radical hysterectomy 
for carcinoma of the uterine cervix, operated between 1993 and 2001 at two cancer centers. Thirty-one patients had prior 
brachytherapy.The median overall operative time was 258 min. The mean number of harvested pelvic external iliac 
nodes was 13.22 per patient. The median postoperative hospital stay was 7.5 days. Two patients had major urinary 
complications; one had a bladder fistula and one ureteral stenosis. Median follow-up was 44 months. Overall 5-year 
survival rate of FIGO stage Ia2 and Ib1 patients was 96%. Their results demonstrated that radical hysterectomy can be 
performed by laparoscopy in stage IB1 or less advanced node negative cervical cancer patients without compromising 
survival; moreover, prior brachytherapy did not affect the feasibility of this radical procedure [94]. 
With technical advances and emerging devices, as well as accumulating experience in laparoscopic surgery, some 
surgical procedures that are difficult to carry out even by traditional open procedures can be performed successfully by 
laparoscopy. 
During the past decade some reports, on a limited number of patients, have shown the feasibility of a radical resection 
by laparoscopic surgery and have documented an equivalent number of pelvic nodes harvested by laparoscopy and 
open surgery [35,42,49,90,91,112]. 
Nevertheless, few long-term data on the morbidity and survival after laparoscopic radical hysterectomy are available. 
Although open radical hysterectomy is still considered the gold standard for the treatment of early cervical cancer [118], 
laparoscopic radical (LRH) and laparoscopy assisted radical vaginal hysterectomy (LARH) are evolving as potential 
surgical alternatives.  
LRH or LARH have been established as standard procedures routinely performed as first line therapy for the treatment 
of early cervical cancer at specialized centers [36,47,79,90]. 
The major advantages associated with minimally invasive laparoscopy are, amongst others, lower intraoperative 
bleeding rates, less post-operative pain, a shorter recovery time and a shorter hospital stay.  
In addition the optical devices used for laparoscopic surgery feature a 10 to 15 times magnification and, therefore, 
provide an excellent view of pelvis anatomy.  
Since Liang Z et al. reported their initial experience with 57 LRH; they have continuously improved and standardized 
the technique [60,97]. 
The indication for laparoscopic surgery was similar to the indication for open surgery in cervical cancer patients. 
According to literature and experience, the indication for laparoscopic radical hysterectomy (type III) and pelvic 
lymphadenectomy was earlier than the FIGO stage IIa in cervical cancer [60].  
However, initially, laparoscopic technique treatment of cervical cancer is associated with a high complication rate so the 
indication must be carefully assessed, and patients have to be counseled extensively prior to surgery. Apart from the size 
and stage of the tumor, the indication for this surgical procedure is mainly influenced by the experience of the surgeon 
[68]. 
More recently, it was reported that stage IIb or more advanced cervical cancer may be treated with type IV radical 
hysterectomy under laparoscopy [16,57,98], as the aim of surgery is to stage and radically resect the tumor (including 
metastases). For certain patients, prolonged survival is the objective of tumor treatment. Through laparoscopic 
exploration, the feasibility and thoroughness of surgery can be evaluated, and the relative benefits of surgery for the 
patient can be weighed. However, it is still controversial what types or what stages of cervical cancer should be adopted 
for laparoscopic surgical treatment. 
Another minimally invasive surgical option used for cervical cancer is laparoscopically assisted vaginal radical 
hysterectomy (LAVRH) or Coelio-Schauta procedure. 
The Coelio-Schauta procedure consists of 2 major steps, 1 laparoscopic and 1 transvaginal.  
Four trocars are inserted, 1 transumbilical, 2 lateral to the inferior epigastric vessels, and 1 in the right lower abdomen. 
Traditionally, laparoscopy has been used to develop the paravesical and pararectal spaces and to perform 
lymphadenectomy of iliac vessels. 
In the transvaginal step, the urinary bladder is dissected from the cervix, the posterior cul-de-sac is opened, and the 
ureters are identified before their insertion into the bladder pilar; then the uterine arteries are ligated, and the cardinal 
ligaments are transected 3 cm from the cervix. Ligation of the utero-ovarian ligaments (or the infudibulopelvic ligaments 
if ovarian preservation is not mandated) is then performed, the round ligament is resected, and the specimen is extracted 
[110].  
A recent review of Pergialiotis et al [85] on LAVRH on Medline (1966-2013) and Scopus (2004-2013), as well as on 
reference lists from all included studies, retrived 10 studies: including 6 retrospective cohort studies, 2 prospective 
cohort studies, 1 retrospective randomized trial, and a phase II randomized control trial.LAVRH provided equal 
recurrence-free rates when performed in patients with tumors not exceeding 2 cm in greatest diameter. Its main 
advantages seem to be less intraoperative blood loss and more radical pelvic lymphadenectomy. The primary 
disadvantages of the technique are a higher rate of disease-positive surgical margins, resulting in the need for adjuvant 
therapy, and the slow learning curve required for a surgeon to gain expertise. 
 
Total laparoscopic radical hysterectomy for cervical cancer 
Laparoscopy can be safely and adequately used in the treatment of endometrial, ovarian and cervical cancer [92].  
In the setting of gynecologic oncology, laparoscopic approaches have been implemented in radical hysterectomy. For 
gynecological oncology laparoscopic surgery is an important step forward combining scientific, technological and 
surgical techniques, which not only enhance the efficacy of surgical treatment of gynecological oncology, but are also 
superior to conventional open surgery with regard to postoperative mental rehabilitation in gynecological oncology 
patients.  
The first total laparoscopic radical hysterectomy with lymphadenectomy was reported in June 1989 by Nezhat et al. [74]. 
Since then, more than 600 cases of total laparoscopic radical hysterectomy have been reported. A recent prospective case-
control series compared total laparoscopic radical hysterectomy with abdominal radical hysterectomy and found shorter 
hospital stays and lower blood loss as well as a statistically significantly higher nodal yield among total laparoscopic 
radical hysterectomy cases [131]. 
Spirtos et al. described 78 patients with early-stage cervical cancer undergoing laparoscopic radical hysterectomy. In that 
series, 94% of the procedures were completed laparoscopical.Mean follow-up time was 67 months. Mean operative time 
was 205 min, and mean blood loss was 225 mL. One patient required a blood transfusion, three patients had unintended 
cystotomies, two patients required laparotomy to control bleeding, and one patient suffered an ureterovaginal fistula. 
Three patients had microscopically positive or close margins. The authors reported a cervical cancer recurrence rate of 
5% [117]. 
Pomel et al. reported 50 patients with stage IA1–IB1 cervical cancer who underwent total laparoscopic radical 
hysterectomy. The median operating time was 258 min, and the mean number of lymph nodes harvested was 13. No 
conversions to laparotomy were reported. Median hospital stay was 7.5 days. The authors reported that 10 patients had 
early complications (within 2 months of surgery) and that three of those patients required reoperation. They also 
reported three patients had late complications (more than 2 months after surgery) two of them requiring reoperation. 
Three patients experienced recurrence with a median follow-up time of 44 months [90]. 
Frumovitz et al. compared 35 patients undergoing total laparoscopic radical hysterectomy with 54 undergoing total 
abdominal radical hysterectomy. Mean estimated blood loss was significantly lower in the laparoscopic-surgery group 
than in the open-surgery group (319 vs. 548 mL; p=0.009). Mean operative time was significantly longer with 
laparoscopic surgery (344 vs. 307 min; p=0.03), but median hospital stay was significantly shorter (2.0 vs. 5.0 days, 
pb0.001). Postoperative infections were much less common after laparoscopic surgery (18% vs. 53%; p=0.001) [31]. 
Notwithstanding the obvious advantages of conventional laparoscopy, recent surveys of practicing gynecologic 
oncologist revealed that most respondents believed minimally invasive surgery by conventional laparoscopy had only a 
minimal role in the management of cervical cancer [30]. 
Puntambekar et al. reported a retrospective review of 248 patients with FIGO stage Ia2 (n=32) and Ib1 (n=216) cervical 
cancer who underwent a TLRH (type III) with bilateral pelvic lymphadenectomy, which is the largest single-institution 
study. The operation was performed entirely by laparoscopy in all patients and by the same surgical team. Median 
operative time was 92 min. Median number of resected pelvic nodes was 18. Median blood loss was 165 ml. Median 
duration of hospital stay was 3 days. None of the patients required conversion to laparotomy. Seventeen patients had 
complications within 2 months of surgery. Seven patients had recurrences after a median 36-month follow-up. They 
concluded that TLRH can be performed safely, reduces morbidity associated with ARH and is an easily replicable 
technique [95]. 
Colombo et al. evaluated surgical outcome and oncologic results of total laparoscopic radical hysterectomy (TLRH) after 
neoadjuvant chemoradiation therapy (CRT) for locally advanced cervical carcinoma. All patients who underwent TLRH 
after CRT for stages IIB–IIA and bulky IB diseases were reviewed. The control group for this analysis was a cohort of 
patients treated with abdominal radical hysterectomy (ARH) after CRT for the same stage cancers. They reviewed 102 
patients operated on between 2000 and 2008 (46 TLRH and 56 ARH). Mean age at diagnosis was 44 years, and mean 
B.M.I was 22.1. There was no difference in tumor characteristics between the two groups. Seven patients in the 
laparoscopic group required conversion to laparotomy (15%). Mean estimated blood loss (200 vs. 400 mL, pb0.01) and 
the median duration of hospital stay (5 vs. 8 days, p<0.01) were significantly lower in the laparoscopic group. Morbidity 
rates and urinary complications were reduced in the laparoscopic group (p=0.04). Local recurrence rates, disease-free 
and overall survival were comparable in the two groups. Best survival was observed for patients with pathological 
complete response or microscopic residual disease compared to patients with macroscopic residues (pb0.01). Authors 
concluded that radical hysterectomy after CRT, with significant morbidity rates, is known to be difficult and remains 
controversial in comparison to exclusive CRT. TLRH after preoperative CRT is feasible in 85% of the cases for patients 
with locally advanced cervical cancer. For these patients, TLRH compared with ARH was associated with favorable 
surgical outcome with comparable oncological results [19]. 
Although laparoscopic surgery has many advantages, it is also associated with a number of potential drawbacks, 
including limited range of intra-abdominal motion (only 4° of freedom), counterintuitive movements, amplification of 
tremors in prolonged cases due to the length and rigidity of the instrumentation, and reduced depth perception 
secondary to a two-dimensional view. 
Naturally, total laparoscopic radical hysterectomy is not without its risks and complications. 
There are still several new challenges to be met regarding theory and enhancement of surgical skils [86].  
Firstly, to form a laparoscopic surgical team, a lot of special requirements relating to both the team members and the 
equipment have to be met, thus restricting the popularization of laparoscopic radical hysterectomy.  
Secondly, every detail should be taken into careful consideration, risks should be balanced and benefits ascertained 
before performing laparoscopic procedures. 
Moreover, it is likely that well-known barriers to the implementation of advanced minimally invasive procedures such 
as association with a long learning curve, lack of training, complexity of the operations, limitation of technology and 
instrumentation, and the necessity of an expert assistant were responsible for this sentiment. 
For these reasons, only a few surgeons have adopted a laparoscopic approach to type III cervical cancer radical. There 
are issues with the length of the procedure, as type III laparoscopic hysterectomies take significantly longer than open 
cases.  
Furthermore, intraoperative complications of the urinary tract (for example as a result of thermal injuries) tend to be 
much more common in laparoscopic than in open cases [130]. 
A recent experience of Malzoni et al. on 71 patients treated by total laparoscopic radical hysterectomy (type II, III) with 
lymphadenectomy was done between January 2000 and March 2008. The authors concluded that total laparoscopic 
radical hysterectomy can be considered a safe and effective therapeutic procedure for the management of early stage 
cervical cancer with a low morbidity, offering an alternative option for patients undergoing radical hysterectomy, 
although multicenter studies and long-term follow-up are required to evaluate the oncologic outcomes of this procedure 
[69]. 
A literature review on laparoscopic radical hysterectomy demonstrates the procedure is also safe and feasible, but is 
associated with an operative time range of 205 min–371 min, an estimated blood loss of 200 cc–445 cc, a nodal yield 
ranging from 13–25, a hospital stay ranging from 1–7.5 days, and an overall complication rate of 11%–20%, as sorted by 
the referenced papers who provide a good cross section of the data [1,67,90,104,117,118]. 
 
Contra-indications to laparoscopic surgery for gynecological oncology 
As previously noted, there are very few absolute contra-indications. However, with increased anesthesia ability, some of 
these may not be considered as absolute 
Severe cardiac diseases could be a problem, since some patients may not tolerate the operation due to the deep 
Trendelenburg positions necessary during most operative laparoscopy in order to maintain an adequate 
pneumoperitoneum. 
Severe patient liver/renal/respiratory dysfunction, which cannot be corrected preoperatively, is also considered to be an 
absolute contraindication. 
Surgeons may refuse laparoscopy for advanced or late stage gynecological tumor in patients with stage III or above 
cervical carcinoma, lymph node metastases of cervical cancer which inter-fuse and encapsulate vital vessels, and/or 
extensive infiltration of adjacent tissues. 
On the other hand, there are few relative contra-indications to laparoscopy for cervical cancer patients; for example, 
severe abdominal adhesions or morbid obesity and so on. 
 
Total robotic-assisted laparoscopic radical hysterectomies 
Today there is only one U.S. Food and Drug Administration approved device for surgical robotics. 
This current robotic platform is known as the "da Vinci" surgical system (Fig. 1), developed by Intuitive Surgical, Inc. 
(Intuitive Surgical, Mountain View, CA, USA). 
The da Vinci surgical system is equipped with a 3-dimensional vision system in which double endoscopes generate two 
images resulting in perception of a 3D image (Fig. 2).  
In addition, with the development of endowrist, it reproduces the range of motion and dexterity of the surgeon hand, 
providing high precision, flexibility and the ability to rotate instruments 360 degrees (Fig. 3). 
Thus, the learning curve of achievement for the surgeons using the da Vinci surgical system was shortened. In 2001, a 
more advanced da Vinci surgical system with four robotic arms gained US FDA approval and is now being used in 
many surgical procedures throughout the world. 
Recently, FDA-approved robotic surgery has become an option in the definitive surgical management of early stage 
cervical cancers.  
Several case series about robotic-assisted radical hysterectomies for cervical cancer have now been published [7,44,65,67-
69]. 
The initial experience and the first publications on robot assistance in gynecological oncology date from recent years.  
In February, 2006, Boggess performed the first live telecast, demonstrating a technique for performing robotic-assisted 
radical hysterectomy and subsequently presented data for a series of 13 radical hysterectomies at the Society of 
Gynecologic Oncologists annual meeting in March of the same year [8]. 
Since this initial demonstration of feasibility and technique, the interest in robotic-assisted gynecologic oncology 
procedures has spread rapidly.  
Recently, Nezhat et al. prospectively compared the outcomes of 13 total robotic-assisted laparoscopic radical 
hysterectomies to 30 cases of traditional total laparoscopic radical hysterectomy with pelvic lymphadenectomy in 
patients with stage IB to IIA cervical cancer. There was no difference in operative time, hospital stay, blood loss, 
complications, or number of nodes retrieved. This study suggests that robotic radical hysterectomy may be a feasible 
alternative to total laparoscopic radical hysterectomy (unpublished data). However, there were no advantages of robotic-
assisted procedures compared to traditional total laparoscopic radical hysterectomy when performed by an experienced 
laparoscopic gynecologic oncologist [76]. 
Fanning et al. reported the first series of robotic radical hysterectomy on 20 women with stage IB–IIA cervical carcinoma. 
Median operative time was 6.5 hours, and median blood loss was 300 mL.No complications were encountered, and all 
patients were discharged home on the first postoperative day. A retrospective cohort study of robotic vs. open radical 
hysterectomy found that the mean blood loss was significantly lower for the robotic group (81.9 vs. 665 mL, p<0.0001), 
but operative time was longer (4.5 vs. 3.39 hours, p=0.0002) [29].  
The mean number of lymph nodes resected did not differ, and no complications were reported in the robotic assisted 
group [45]. 
Furthermore, laparoscopic radical hysterectomy studies, although variable, report an operating times from 92 to 350 
minutes, an estimated blood loss of 165 ml, and a length of stay of three days, whereas for robotic surgery comparable 
figures are 190-370 minutes, 140 ml, and two days [24,59,92,131]. 
The first radical hysterectomy in cervical cancer with robot assistance was described by Sert and Abeler. They concluded 
that radical dissection could be performed much more precisely than with conventional laparoscopy. In 2007, they 
described 15 women with early-stage cervical cancer as a pilot case–control study and compared robotic-assisted 
laparoscopic radical hysterectomy with conventional total laparoscopic radical hysterectomy. There was a significant 
difference in mean operating time (241 minutes in the robot group and 300 minutes in the conventional group). No 
difference in the number of lymph nodes and size of parametrial tissue was found. In the robot group, there was 
significant less bleeding and shorter hospital stay [113]. 
Kim et al. performed robotic radical hysterectomy and pelvic lymphadenectomy in ten cases and found a mean 
operating time of 207 minutes. The mean docking time was 26 minutes, but this was reduced significantly with 
experience (from 35 to 10 minutes) [44]. 
These small series, however, do not report the outcome of surgery in terms of lymph node yield and radicality and also 
lack sufficient oncological follow up.  
Boggess found no difference in the operating time (242 versus 240 minutes) [6]. He performed 13 robot-assisted radical 
hysterectomies and compared them with 48 open radical hysterectomies. Significantly more lymph nodes were collected 
in the robot group (33 versus 22). All the robotic patients were discharged within 24 hours. He also describes how to set 
up a robotic program in gynaecological oncology.  
Recently, a study of Lowe et al. reported a multi-institutional experience with robotic-assisted radical hysterectomy in 
patients with early stage cervical cancer with respect to peri-operative outcomes. In their investigation, a multi-
institutional robotic surgical consortium consisting of five board-certified gynecologist oncologists in distinct 
geographical regions of the United States was created, in order to evaluate the utility of robotics for gynecologic surgery 
(benign and malignant). Between April 2003 and August 2008, a total of 835 patients underwent robotic surgery for 
benign gynecologic disorders and/or gynecologic malignancies by a surgeon in the consortium. For the purpose of the 
study, a multi-institutional HIPPA compliant database was then created for all patients. In the results, from a database of 
835 patients who underwent robotic surgery by a gynecologic oncologist they identified, a total of 42 patients who 
underwent a robotic-assisted type II (n=10) or type III (n=32) radical hysterectomy for early stage cervical cancer. With 
regard to stage, seven patients (17%) were Stage IA2, twenty-eight patients (67%) were Stage IB1 and six patients (14%) 
were Stage IB2. There was a single patient with Stage IA1 cervical cancer with vascular space invasion who underwent 
type II radical hysterectomy. Overall median operative time was 215 min. Overall median estimated blood loss was 50 
cc. No patient received a blood transfusion. Median lymph node count was 25. Median hospital stay was 1 day. Positive 
lymph nodes were detected in 12% of the patients. Pelvic radiotherapy or chemo-radiation was given to 14% of the 
patients based on final surgical pathology. Intraoperative complications occurred in 4.8% of the patients and included 
one conversion to laparotomy (2.4%) and one ureteral injury (2.4%). Postoperative complications were reported in 12% of 
patients and included a DVT (2.4%), infection (7.2%), and bladder/urinary tract complication (2.4%) Conversion rate to 
laparotomy was 2.4%.In their conclusions, Lowe et al. reported that robotic-assisted radical hysterectomy is associated 
with minimal blood loss, a shortened hospital stay, and few operative complications. Operative time and lymph node 
yields are acceptable. This data suggests that robotic-assisted radical hysterectomy may offer an alternative to traditional 
radical hysterectomy [61].  
Persson et al. reported their experience in 80 robot-assisted laparoscopic radical hysterectomies to evaluate its feasibility 
and morbidity, from December 2005 to September 2008. They used a prospective protocol, and an active investigation 
policy to define adverse events, perioperative, and short and long term data. Also in their conclusions, authors showed 
that robot- assisted laparoscopic radical hysterectomy could be a feasible alternative to conventional laparoscopy and 
open surgery, even if efforts should be made to ensure proper closure of the vaginal cuff, trocar sites and to develop 
nerve sparing techniques [87]. 
Cantrell et al. assessed progression-free and overall survival for women with cervical cancer who underwent type III 
robotic radical hysterectomy, in a retrospective analysis of women who underwent RRH from 2005 to 2008. They were 
compared to a group of historical open radical hysterectomies. They analyzed seventy-one women who had undergone 
attempted RRH during the study period. Eight were excluded from analysis: 4 for non-cervical primary and 4 cases were 
aborted due to the extent of the disease. Squamous was the most common histology (62%) followed by adenocarcinoma 
(32%). Median patient age was 43 years. There was one intraoperative complication (asystole after induction) and two 
postoperative complications (ICU admission to rule out myocardial infarction and reoperation for cuff dehiscence). Of 
the patients who underwent RRH, 32% received whole-pelvis radiation with chemo sensitization. Median follow-up was 
12.2 months (range 0.2–36.3 months). Kaplan–Meier survival analysis demonstrated 94% PFS and OS at 36 months due to 
recurrence and the death of one patient. As compared with a historical cohort at our institution, there was no statistically 
significant difference in PFS (P=0.27) or OS (P=0.47). In the conclusions, Cantrell et al. reported that RRH is safe and 
feasible and has been shown to be associated with improved operative measures. This study showed that at 3 years, 
RRH appears to have PFS and OS equivalent to that of traditional laparotomy. While the 5-year data are not yet available 
for the cohort of patients treated with robotic surgery, the 94% survival upon 3 years of performing RRH is comparable 
to other surgical methods and radiation [13]. 
 
The problem of lymph-node in endoscopic lymphadenectomy 
The limitations of FIGO clinical staging involve the possibility to detect metastases to lymph nodes, using clinical staging 
alone. This leads to under staging of some patients [52,56]. Failure to detect metastasis to para-aortic nodes in patients 
with locally advanced cervical cancer leads to suboptimal treatment. One option consists of evaluating lymph node 
invasion using imaging techniques. However, as reported recently, false negative rates as high as 11% have been 
reported when comparing PET to lymphadenectomy in advanced cervical cancer [73]. Ramirez et al. compared positron 
emission tomography (PET)/computed tomography (CT) with laparoscopic extraperitoneal staging in the evaluation of 
para-aortic lymph nodes. The sensitivity and specificity of PET/CT in detecting positive para-aortic nodes when nodes 
were negative on CT or MRI were 36% and 96%, respectively. The PPV and NPV of PET/CT for para-aortic metastasis 
were 71% and 83%, respectively. For the subset of patients with positive pelvic lymph nodes on preoperative PET/CT, 
the sensitivity of PET/CT for identifying para-aortic lymph node metastases was 45%, the specificity was 91%, the PPV 
was 71%, and the NPV was 78%.[84]. Therefore, another option is to perform surgical staging [47,71,93]. 
Laparoscopic para-aortic node sampling has been shown to be feasible in gynecological malignancies. In addition, it is 
associated with lower morbidity than staging using laparotomy [20,25,96,99,116,127]. Its only technical limitation occurs 
in obese patients. However, using the classical laparoscopic approach, the surgeon is limited in the degrees of his 
movements. By assisted-robotic surgery, this problem could be solved. The feasibility of a robotically assisted 
retroperitoneal approach, to dissect lower lumbo-aortic lymph nodes, was reported recently. Simultaneously to Vergote 
et al. [128], Fastrez et al.[30],  evaluated the feasibility and safety of a robot-assisted laparoscopic transperitoneal 
approach of the para-aortic lymph node dissection on 8 patients with advanced cervical carcinoma who were eligible for 
primary pelvic radiotherapy combined with concurrent cisplatin chemotherapy or pelvic exenteration and who 
underwent a pre-treatment robot assisted transperitoneal laparoscopic para-aortic lymphadenectomy. Authors isolated 
from 1 to 38 para-aortic nodes per patient and had one para-aortic node positive patient who was treated with extended 
doses of pelvic radiotherapy. We did not encounter any major complications and post-operative morbidity was low. In 
the conclusions, Fastrez reported that robot assisted transperitoneal laparoscopic para-aortic lymphadenectomy is 
feasible and provides the surgeon with greater precision than classical laparoscopy, even if larger prospective 
multicentre trials are needed to validate the generalized usefulness of this technique [30]. 
The technique of the robotic retroperitoneal para-aortic lymphadenectomy has been described by Vergote et al., who 
reported the feasibility of robot-assisted laparoscopic retroperitoneal para-aortic lymphadenectomy in five patients [128]. 
In 2008 Ramirez et al. described a series of patients diagnosed with invasive cervical cancer after undergoing simple 
hysterectomy who subsequently underwent robotic radical parametrectomy and bilateral pelvic lymphadenectomy. In 
their results, authors included 5 patients in analysis, with invasive squamous cell carcinoma of the cervix. There were no 
conversions to laparotomy. There was 1 intraoperative complication—cystotomy. No patient required blood transfusion. 
The mean duration of hospital stay was 1 day (range, 1 to 2). One patient experienced two postoperative complications, a 
vesicovaginal fistula and a lymphocyst. No patient had a residual tumor in the parametrectomy specimen, and no 
patient underwent adjuvant therapy. Median number of pelvic lymph nodes removed was 14 (range, 6 to 16). Median 
follow-up for all patients was 7.5 months (range, 1.3 to 13.8), without recurrences. In conclusion, Ramirez assessed that 
robotic radical parametrectomy and bilateral pelvic lymphadenectomy is feasible and safe and can be performed with an 
acceptable complication rate [103]. 
Robotic assistance with the Da Vinci system provides the surgeon with more precise dissection conditions, thanks to the 
three-dimensional visualization, instrumentation with articulating tips, that allows the surgeon's hands more mobility 
and decreases tremor movements.  
This increased precision in procedure as compared with classical laparoscopy is particularly important in the para-aortic 
region and may enhance safety and decrease intraoperative morbidity. 
 
Fertility-sparing surgery in cervical cancer 
The incidences of cervical cancer is increasing in young women and women are delaying their childbearing. Available 
literature shows that there are interesting fertility-sparing treatment alternatives to the “golden standard” for the 
management of early cervical cancer in young women. So, the fertility-sparing surgery become an option for young 
women affected by cervical cancer. Fertility-sparing surgery can be offered to carefully selected patients with cervical 
cancer for the management of early-stage (IA or IB1) disease who wish to preserve fertility [54]. 
Simple trachelectomy (cervicectomy) and radical trachelectomy (resection of parametrial tissue with cervix) are being 
used in women with early stage disease. Cervical conization used in preinvasive cancer as investigative biopsy could 
also become a therapy. 
Randomized controlled trials of fertility-preserving surgery are impractical and unfeasible; however, radical 
trachelectomy has been retrospectively shown to have similar oncologic outcomes to radical hysterectomy in select 
patients with stage IB1 cervical cancer. 
In patients with stage IA1 cervical cancer, conization is a valid alternative. Patients with stage IA2-IB1 disease can be 
conservatively treated by radical trachelectomy. This is as well-established conservative approach and appears to be safe 
and effective in allowing a high chance of conception [55]. 
Prematurity is the most serious issue in pregnancies following trachelectomy. Less invasive options such as simple 
trachelectomy or conization seem to be feasible for stages IA2-IB1, but more and better evidence is needed. Neoadjuvant 
therapy might allow conservative surgery to be performed, also in patients with more extensive lesions. Ovarian 
transposition is important when adjuvant radiation is needed [78].  
Trachelectomy has been adopted by many oncological centers all over the world with good oncological and obstetric 
results. The selection of patients by adequate preoperative evaluation is an important process before a decision regarding 
conservative treatment is taken. Lesionextent is of great importance; the tumor should be small in size and confined to 
the cervix without parametrial invasion or spread to the uterine corpus. A 19% recurrence rate has been reported for 
patients with lesions >2 cm and 25% for those with lesions >2 cm and depth of invasion >1 cm [53,103]. 
Radical trachelectomy is performed in select patients diagnosed with early-stage cervical cancer who wish to preserve 
their fertility. 
Since the procedure was first described by Dargent et al. in 1994 [21], numerous reports have documented the safety and 
feasibility of the vaginal approach [4,27,37,89,125].  
Alternatively, the procedure may also be performed successfully via the abdominal approach. Several groups have 
published works on the success rate and feasibility of the abdominal approach [34,83]. 
The first to report on robotic radical trachelectomy were Geisler et al., who reported on a patient with stage IB1 cervix 
adenosarcoma. In this case, total operative timewas 172 min, and the estimated blood loss was 100 ml. No residual tumor 
was found in the surgical specimen, and all lymph nodes were negative for any evidence of disease [34]. 
Persson et al. published on 2 patients who underwent robotic radical trachelectomy. One patient was diagnosed with a 
stage IB1 cervix adenocarcinoma and the other with a stage IA2 squamous cervix carcinoma. This group of investigators 
was the first to publish on robotic radical trachelectomy in conjunction with lymphatic mapping and sentinel node 
identification. In that study, console time was 387 min for the first patient and 359 min for the second. Estimated blood 
loss was 150 ml for the first patient and 100 ml for the second. The authors reported no intraoperative complications. 
Neither patient had residual cancer or evidence of lymph node disease [86]. 
Chuang et al. described a robotic radical trachelectomy in a young woman with cervical cancer who desired preservation 
of fertility; the patient had previously undergone a cervical conization procedure, with negative margins. 
Findings at positron emission tomography and computed tomography were normal, and there was no evidence of 
metastasis before surgery. The operation lasted 345 minutes, with 200 mL blood loss. Final pathologic analysis showed 
no evidence of residual cancer. All reported cases were completed successfully and highlight robotic-assisted 
laparoscopy as a useful approach to trachelectomy in appropriate patients [18].  
As one could argue that parametrectomy is not necessary for small tumours, it is relevant that this approach allows one 
to tailor the extent of parametrectomy according to the size of the tumour. Potentially, this minimally invasive approach 
may also overcome a severe disadvantage of abdominal trachelectomy, namely that pregnancy rate is much lower than 
after vaginal radical trachelectomy, but series are as yet too small to assess this potential benefit. 
The robotic approach also seems safe in cases where surgery follows neoadjuvant chemotherapy for locoregional 
extensive tumours. In a study comparing robot-assisted laparoscopy, conventional laparoscopy and laparotomy groups, 
there was no difference in the recurrence rate (27.3 %, 29.4 % and 30 %, respectively) [10,21]. 
Ramirez et al. described their surgical technique in a retrospective review on 4 patients who underwent robotic radical 
trachelectomy and bilateral pelvic lymphadenectomy from October 2008 to May 2009. Their analysis included 4 patients 
with early-stage squamous cell carcinoma of the cervix. The median body mass index was 27.1 kg/m2 (range, 22.7 to 
39.1). Three patients had stage IA2 adenocarcinoma; 1 patient had stage IA1 adenocarcinoma with lymph-vascular space 
invasion. Median operative time was 339.5 min (range, 245 to 416). Median console time was 282.5 min (range, 217 to 
338). Median estimated blood loss was 62.5 ml (range, 50 to 75). There were no conversions to laparotomy. There were no 
intraoperative complications. No patient required blood transfusion. The mean duration of hospital stay was 1.5 days 
(range, 1 to 2). One patient experienced a postoperative complication, transient left lower extremity sensory neuropathy. 
No patient had residual tumor in the trachelectomy specimen, and no patient underwent adjuvant therapy. The median 
number of pelvic lymph nodes removed was 20 (range, 18 to 27). The median time to a successful voiding trial was 8 
days (range, 7 to 9). The median follow-up was 105 days (range, 82 to 217). There were no recurrences. Ramirez et al. 
concluded that robotic radical trachelectomy and bilateral pelvic lymphadenectomy is feasible and safe and should be 
considered for patients desiring fertility-sparing surgery [102]. 
There is increasing evidence in literature that not only is radical trachelectomy feasible and safe but the oncologic 
outcomes are similar to those of equivalent patients undergoing radical hysterectomy.  
In a recent article, Diaz et al. [26] compared the outcomes of 40 patients with stage IB1 cervical cancer who underwent 
radical trachelectomy and 110 patients with stage IB1 cervical cancer who underwent radical hysterectomy. The median 
follow-up time was 44 months. The 5-year recurrence-free survival rate was 96% for the radical trachelectomy group 
compared to 86% for the radical hysterectomy group (p=NS). The authors concluded that for select patients with stage 
IB1 cervical cancer, fertility-sparing radical trachelectomy appears to produce oncologic outcomes similar to those after 
radical hysterectomy. 
Recently, many studies analysed the reproductive outcome after fertility-sparing radical trachelectomy. One of these 
studies was performed by Kim et al. in 2012 on 105 patients who underwent RT [43]. 77 (73%) did not require a 
conversion to radical hysterectomy or postoperative treatment. Median age was 32 (range, 25-38 years). Most patients 
(75%) had stage IB1 disease. Sixty-six patients (63%) were nulliparous. Thirty-five women were actively attempting 
conception 6 months after surgery, and 23 (66%) women were successful in conceiving: there were 20 live births, 3 
elective terminations, and 4 spontaneous miscarriages. Four patients had 2 pregnancies each; all delivered their second 
pregnancy between 32 and 36 weeks. Cerclage erosion through the vaginal wall occurred in 6 cases and was treated by 
transvaginal removal of protruding suture material. One of these patients experienced a second trimester miscarriage. In 
conclusion: the majority of women who attempted to conceive after radical trachelectomy were successful, and most of 
their pregnancies resulted in full-term births [43].  
Finally, even more intriguing, recent studies have suggested that even more conservative techniques such as cervical 
conization, with or without pelvic lymphadenectomy, may be applicable in treatment of early-stage cervical cancer 
including stage IB1[70]. 
If the surgical community accepts the findings of these early reports, minimally invasive techniques including simple 
conization or trachelectomy plus lymphadenectomy may need to either become more challenging, with cases with more 
advanced presurgical staging, or totally lose ground as treatment alternatives. 
Assisted reproduction played an important role in select women. Cerclage likely contributed to a post-trachelectomy 
uterine ability to carry a pregnancy to the third trimester. The second post-trachelectomy pregnancy appears to be at 
higher risk for preterm delivery than the first pregnancy. In term of histopatological outcomes there is no evidence. 
 
Comparison between laparoscopy and robotic in radical hysterectomy 
There is a growing trend to practice less aggressive surgery in order to preserve fertility in young women and avoid an 
excess of treatment in some selected patients and nerve-sparing techniques can help to improve the quality of life. 
Laparoscopic robotic-assisted radical hysterectomy with nerve sparing technique is an attractive surgical approach for 
early invasive cervical cancer. Robotic technology allows a stereoscopic visualization of blood vessels and autonomic 
nerve supplies (sympathetic and parasympathetic branches) to the bladder and rectum making nerve sparing a safe and 
feasible procedure [35]. 
Magrina and colleagues recently presented the first prospective study comparing the perioperative results of patients 
undergoing radical hysterectomy and lymph node dissection by robotics, laparoscopy and laparotomy [65]. Mean 
operating time for a robotic, laparoscopic and radical hysterectomy per laparotomy was 190, 220 and 167 min, 
respectively; mean blood loss was 133, 208 and 444 mL respectively; mean number of removed lymph nodes was 26, 26 
and 28, respectively, and mean hospital stay was 1.7, 2.4 and 3.6 days, respectively. There were no significant differences 
in intra- or postoperative complications among the three groups and no conversions in the robotics or laparoscopic 
groups. At a mean follow up of 31 months, none of the patients with cervical cancer experienced a recurrence. The 
authors concluded that laparoscopy and robotics are preferable to laparotomy for patients requiring radical 
hysterectomy, with advantages like significantly shorter operating times noted for robotics over laparoscopy [65]. 
Their results are in accordance with other groups, although some reported the feasibility of a more radical lymph node 
dissection with the robotic system when compared to conventional laparoscopy [7,44]. 
Several case reports suggest that debulking surgery is a further potential application for robotics surgery in 
gynaecological oncology [15,126]. 
In a recent paper, Cho and Nezhat compared robotic and laparoscopy in gynecological oncology [17]. The objectives of 
their article were to review the published scientific literature about robotics and its application to gynecologic oncology 
to date and to summarize findings of this advanced computer enhanced laparoscopic technique. Relevant sources were 
identified by a search of PUBMED from January 1950 to January 2009 using the key words Robot or Robotics and 
Cervical cancer, Endometrial cancer, Gynecologic oncology, and Ovarian cancer. Appropriate case reports, case series, 
retrospective studies, prospective trials, and review articles were selected. A total of 38 articles were identified on the 
subject, and 27 were included in the study. The data for gynecologic cancer show comparable results between robotic 
and laparoscopic surgery for estimated blood loss, operative time, length of hospital stay, and complications. Overall, 
there were more wound complications with the laparotomy approach compared with laparoscopy and robotic-assisted 
laparoscopy. There were more lymphocysts, lymphoceles, and lymphedema in the robotic-assisted laparoscopic group 
compared with the laparoscopy and laparotomy groups in patients with cervical cancer. Overall, 126 robotic-assisted 
laparoscopies, 68 laparoscopies, and 136 laparotomies were performed in the cohort studies of cervical cancer, each with 
varying intraoperative and postoperative issues. In the robotic-assisted laparoscopy group, there were 24 complications, 
with lymphocysts or lymphoceles, infections, and vaginal cuff complications most commonly reported. In the traditional 
laparoscopy group, there were 16 complications, with lymphocysts or lymphoceles and infections most commonly 
reported. In the laparotomy group, there were 24 complications, with adverse wound and gastrointestinal sequelae most 
commonly reported. 
Computer-enhanced technology may enable more surgeons to convert laparotomies to laparoscopic surgery with its 
associated benefits. It seems that in the hands of experienced laparoscopic surgeons, final outcomes are the same with or 
without use of the robot [17].  
Lambaudie et al. compared the feasibility and efficacy of 22 robot-assisted laparoscopies with 20 traditional laparotomy 
and 16 conventional laparoscopy in a series of patients with locally advanced cervical cancer managed in two 
institutions. 
In the results, there was no significant difference between the three groups in terms of body mass index, FIGO stage, or 
tumor histology. Complication rate was similar in the three groups of patients, although there was a trend towards more 
lymphatic complications in the robot-assisted subgroup managed medically. There was no significant difference in the 
recurrence rate between the robot-assisted laparoscopy, conventional laparoscopy and laparotomy groups (27.3%, 29.4% 
and 30%, respectively). 
Authors concluded that robot-assisted laparoscopy is feasible after concurrent chemoradiation and brachytherapy in 
cases of locally advanced cervical cancer, reduces hospital stay, and seems to result in less severe complications than 
conventional laparotomy without modifying the oncological outcome [53]. 
 
Complications of endoscopy in cervical cancer 
Robotics, like any novel technology, has its advantages, disadvantages and reported complications. 
In the modern era of minimally invasive techniques, current developments in surgical robotics represent only the initial 
attempts to simplify complex laparoscopic procedures, providing precision in dexterity and perfection of repetitive tasks 
such as suturing. 
The current evidence shows that minimally invasive surgery is associated with less morbidity compared with open 
surgery and can be considered as an alternate option for surgical management of cervical cancer without compromising 
the oncologic outcome. There are several studies in literature, which compared laparoscopic or robotic surgeries with 
open method. In a majority of the studies, the operating time for laparoscopy was higher compared with the open 
method [59,69]. 
In comparative studies, laparoscopic and robotic methods were associated with shorter hospital stay when compared to 
the open method. Mean blood loss and transfusion rates were more for the open method. In a comparative study 
between laparoscopic and robotic radical hysterectomy, Farr R. Nezhat, MD, M. Shoma Datta et al. showed that there is 
no difference between operating time, hospital stay, mean pelvic lymph node yield or intraoperative or postoperative 
complications between the robotic and laparoscopic method [77]. 
The complication rates of robotic radical hysterectomy are lower compared to our historical cohort of radical 
hysterectomy by standard laparotomy. 
Many authors and surgeons affirm that some complications may be associated with robotic or laparoscopic surgery per 
se. 
The frequent reported complications are on vaginal cuff (dehiscence, lymphatic leaking, infection , hematoma, vault 
prolapse, short vagina), on the lymphatic system (proximal lymphedema, mild distal lymphedema, severe distal 
lymphedema, lymphocyst), on the neural peripheral system (genitofemoral nerve injury, partial obturator nerve palsy), 
on the abdominal wall (port site hernia, port site muscle rupture, hematoma, port site metastases) and the vascular 
system (postop hemoglobin and/or transfusion, ovarian vein thrombosis and pulmonary embolism). 
Symptomatic postoperative lymphocysts (SPOLs) and lower-limb lymphedema (LLL) are probably underestimated 
complications of lymphadenectomy for gynecologic malignancies. 
Adjuvant radiotherapy was significantly associated with the development of lymphedema in women who had 
undergone radical surgery with lymphadenectomy for FIGO stage I to stage IIA cervical cancer (odds ratio, 3.47; 95% 
confidence interval, 2.086-5.788; P = 0.000) [43] 
Moreover, there are also risks of infection by pneumonia, with pyelonephritis and/or fever of unknown origin, a risk of 
ureter stenosis and of uncorrected positioning, with arm/shoulder/leg pain. 
In the Piver study, there were 2 deaths (one from pneumonia and one from pelvic abscess), 2 pulmonary emboli, one 
ureterovaginal fistula and one ureteral stricture and a total of 15 complications in 55 patients who underwent type III 
open radical hysterectomy (27%). 
Moreover, Piver and colleagues showed a 5-year disease-free interval of 87.5–100% in women with cervical cancers less 
than 3 cm treated by type III radical hysterectomy [88]. 
About the incidence of port site hernia and/or dehiscence after laparoscopic surgery and robotic assisted surgery in 
oncology, literature has recent evidences. 
The incidence of port site hernia and/or dehiscence using bladeless trocars is 0-1.2%. Robotic surgery uses additional 
port sites and increases manipulation of instruments, raising the concern for more complications. Authors reviewed 
Robotically-assisted (RA) 842 procedures performed for suspected gynecologic malignancy between 1/2006 and 
12/2011. Bladeless 12mm and 8mm robotic trocars were used. Fascial closure was not routinely performed except after 
specimen removal through the port site. The decision to close the fascia remained at the discretion of the surgeon. RA-
total laparoscopic hysterectomy (TLH)±unilateral or bilateral salpingo-oophorectomy (BSO)±lymphadenectomy (LND) 
accounted for 91.6% of procedures. Final pathology confirmed malignancy in 58.6% of cases, primarily endometrial 
cancer. In 35 cases, the specimen was removed through the port site; fascia was closed in 54.3% of them and no port site 
hernias or dehiscences occurred. In the study conclusion, authors affirmed that port site hernias and dehiscences are rare 
in RA gynecologic oncology procedures. When bladeless dilating trocars are used, routine closure of even up to a 12mm 
port site is unnecessary, even in cases requiring removal of the specimen through the trocar sites [9]. 
 
Literature drawbacks concerning robotic surgery in gynaecological oncology 
In recent years, robotic surgery or robot assisted surgery has been developed to support a range of surgical procedures. 
Robotic surgery in cervical and endometrial cancer is one of the fastest growing areas. 
Robotic surgical systems have been used to perform surgery for endometrial, cervical cancer and ovarian cancer. There is 
mounting evidence which demonstrates the feasibility and safety of robotic surgery for gynaecological oncology. 
Cochrane Gynaecological Cancer Group evaluated in 2012 all randomised controlled trials (RCTs) comparing robotic 
assisted surgery for gynaecological cancer to laparoscopic or open surgical procedures as well as RCTs comparing 
different types of robotic assistants. 
To review authors independently screened studies for inclusion and no RCTs were identified [62]. 
The robotic approach was explored in a study of 2010 by Lambaudie et al; it seemed safe in cases where surgery follows 
neoadjuvant chemotherapy for locoregional extensive tumours. In a study comparing robot-assisted laparoscopy, 
conventional laparoscopy and laparotomy groups, there was no difference in the recurrence rate (27.3 %, 29.4 % and 30 
%, respectively) [53]. 
Although already known to be commoner after laparoscopic hysterectomy than after laparotomy [14], a particularly 
striking finding is a relative high number, up to 20 %, of patients with vaginal dehiscence after robot-assisted 
laparoscopic surgery [87].  
This may be explained by the initial use of extensive cautery or tight suturing, causing necrosis. Although some authors 
reported a significant decrease in vaginal cuff dehiscence when closing the vagina vaginally instead of laparoscopically 
[124], others did not find a difference between the methods of closure [39].  
In recent series, this complication seems to occur less prominently than in the past, maybe due to caution with cautery 
and the use of self-locking sutures. 
Published experience has suggested that the outcomes with Robotic Radical Hysterectomy (RRH) are similar to that for 
patients undergoing a traditional radical hysterectomy via an exploratory laparotomy [13,28,63]. 
These primarily single institution series have compared primarily surgical outcomes of patients undergoing RRH with 
Laparoscopic RH and/or Abdominal RH.  
Secondary to the relatively recent introduction of roboticassisted radical hysterectomies, limited information regarding 
oncologic outcomes specifically in terms of survival is available. Overall, these studies have suggested that robotic 
surgery is generally longer, with less estimated blood loss and similar nodal yield.  
Lowe et al. [61] reported their multi-institutional experience in a group of 42 patients undergoing Type II or III RRH. 
Overall 42 patients underwent either a Type II or III RRH with operative outcomes similar to other series and an overall 
low complication rate of 4.8%. 
Many authors affirmed that robotic total laparoscopic radical hysterectomy with pelvic and para-aortic 
lymphadenectomy is feasible and may be preferable over laparoscopic or radical abdominal hysterectomy. They 
reported advantages to both minimally invasive approaches, with decreased average estimated blood loss, length of 
stay, number of catheter days, days on pain medication, and a faster return to work in both the robotic and laparoscopic 
groups when compared to laparotomy. 
Even with increased visualization and surgical precision, complications still may occur.  
A large review from Kho et al. [41] at the Scottsdale Arizona Mayo Clinic of >500 patients undergoing various robotic-
assisted surgical procedures noted a 4.1% (95% CI 2.3–5.8%) vaginal cuff dehiscence rate. Of these 21 patients, 9 (43%) 
had a pre-operative diagnosis of cancer including 3 with cervical carcinoma.  
This rate is similar to the 7.5% incidence seen in the cervical cancer series from Italy by Maggioni et al [63], although as 
they note in their follow-up letter to the editor, following a modification in surgical technique, the incidence in their 
patients has decreased to 1% [114].  
Although unlikely, based on the size of the predicted fascial defect, herniation of small bowel through an 8-mm robotic 
trocar has been reported [111]. 
The published data comparing different surgical approaches to radical hysterectomy, including traditional laparoscopy 
or laparotomy show that the robotic approach produces more favorable perioperative outcomes, such as less blood loss, 
abbreviated hospitalizations, and equivalent or lower rates of intraoperative and postoperative complications. While 
these series are relatively small and non-randomized, they consistently demonstrate safety and efficacy with respect to 
complications, blood loss, operative time and patient convalescence comparing robotic assisted surgery with 
laparoscopy [28,65,76,119]. 
Despite that these findings are consistently reproducible in larger and multi-institutional studies, there are no 
prospective data to resolve these unequivocal comparisons in cervical cancer patients. We hope that the prospective 
randomized controlled trial that is currently ongoing will provide further insight. 
Although robotic-assisted technology is supposedly an enhancement of conventional laparoscopy, several studies have 
reported conversion of the robotic approach to laparotomy, not laparoscopy. There were 6 conversions from robotic-
assisted laparoscopy to laparotomy in 2 studies [6]. 
 
Pro and contra of robotic assisted surgery 
In 2005, the first feasibility studies in both Europe and the United States were published, since robotic-assisted 
procedures provide several advantages.  
Binocular vision and 3-dimensional views permit improved depth perception, which may facilitate advanced 
laparoscopic procedures, such as intracorporeal suturing. The console is located away from the patient and permits the 
surgeon to operate in a comfortable, seated position, thus making operator positioning more ergonomic. 
Tremor filtration is another benefit of robotic-assisted surgery, as the video laparoscope is no longer in a human hand, 
which may tire or move, but rather is fixed in position by the robotic arm.  
This feature permits finer surgical movements with more precise dissections.  
The articulating instrument tips that are utilized in traditional laparoscopy are taken to a new level with not only 
rotational capabilities but an independent 90-degree articulation of the tip.  
These features make robotic surgery more intuitive, with a shorter learning curve. Additional robotic arms have been 
introduced to further minimize the need for surgical assistants in institutions that may have limited staff. 
Robotic-assisted procedures are not, however, without their limitations.  
The equipment is still very large, bulky, and expensive. The staff must be trained specifically on draping and docking the 
apparatus to maintain efficient operative times. 
Functional limitations include lack of haptic feedback, limited vaginal access, limited instrumentation, and larger port 
incisions requiring fascial closure. In terms of haptic feedback, visual cues become imperative to ensure that tissue 
manipulation is not performed with undue force. Intracorporeal knots must be tied carefully such that the suture is not 
avulsed by the strength imposed by the robotic arm.  
Limited vaginal access can be problematic in gynecologic surgery as frequent uterine or vaginal manipulation is 
necessary, particularly in extirpative procedures.  
Once the robot has ascended into place, access to the vagina becomes markedly limited. Robotic accessory trocars are 8 
mm in size with a 12 mm laparoscope. 
These incision sizes are larger than the 5 mm accessories that are frequently used in traditional laparoscopy and also 
require fascial closure, with higher risks of herniation.  
The robot is also limited in its instrumentation. Exchanging instruments becomes more cumbersome and requires a 
surgical assistant to change the instruments.  
Additionally, the current robotic instruments do not include endoscopic staplers or vessel sealing devices. Moreover, the 
trocars required for robotic procedures are larger than those used for traditional laparoscopy. In radical hysterectomy, 
the dissection of the uterine arteries, ureteral tunneling, and vaginal cuff closure are among the most useful indications 
for robotic-assisted procedures. The greater range of motion afforded by the robotic instruments permits easier 
maneuverability for these dissections. 
These multiple optional of robotic-assisted surgery had been evaluated by literature.  
A recent paper on robotics has definitely been shown that robotic surgeries are more costly than regular laparoscopic 
approaches [115].  
Nevertheless, one study found an additional $3000 in operative case per robot-assisted vs laparoscopic hysterectomy 
[40]. 
This cost differential may change with a decrease as other robotic systems come on line in the future. 
Moreover, another blinded, prospective randomized controlled trial comparing operative time and intra- and 
postoperative complications between total laparoscopic hysterectomy and robotic-assisted total laparoscopic 
hysterectomy, concluded that, although laparoscopic and robotic-assisted hysterectomies are safe approaches to 
hysterectomy, robotic-assisted hysterectomy requires a significantly longer operative time. The lengthier times in the 
robot group are likely due to operating room set up, docking time, troubleshooting of technical aspects that may be 
faulty with the robot (eg, collision of arms, malfunctioning instrumentation), and less efficient electrosurgical vessel-
sealing instrumentation for robot-assisted surgery during the time that this trial was undertaken [82]. 
A recent investigation show that robotic-assisted laparoscopy is safe, effective, and successful in obese and morbidly 
obese patients who undergo hysterectomy for malignancy which further decreases the incidence of laparotomy in the 
future [58] and an American study on 1000 cases on robotic surgery (RS) in oncology from May 2006 through December 
2009, analyzed patient characteristics and outcomes on a total of 377 women undergoing RS for endometrial cancer 
staging (ECS), compared with the historical data of 131 undergoing open ECS. Authors concluded that RS is associated 
with favorable morbidity and conversion rates in an unselected cohort. Compared to laparotomy, robotic ECS results in 
improved outcomes [81]. 
Thus, after data revision, robot-assisted hysterectomy does not confer any perioperative patient benefits over 
laparoscopic hysterectomy in the hands of experienced conventional laparoscopic surgeons, except in gynecological 
oncology, where robotics have advantages [107].  
 
Conclusions 
The robotic-assisted surgery has emerged as an invaluable minimally invasive approach to comprehensive surgical 
staging and the treatment of cervical cancer. There is good evidence that robotic surgery facilitates laparoscopic surgery, 
with equivalent if not better operative time and comparable surgical outcomes, shorter hospital stay, and fewer major 
complications than with surgeries using the laparotomy approach. And the role of robotic-assisted surgery is still 
expanding [50]. 
In addition to radical hysterectomy, gynecologic oncologists are applying robotic technology to ovarian transposition, 
lymphadenectomy, and even tumor debulking.  
Some future directions that will further the scope of robotic-assisted surgery include incorporation of the robotic system 
in the operating room facility to permit better accessibility to the patient during the procedure as well as expansion in 
instrumentation. 
Total laparoscopic radical hysterectomy is a feasible and safe procedure that is associated with fewer intraoperative and 
postoperative complications than abdominal radical hysterectomy. 
Longer follow-up is needed, but early data are supportive of at least equivalent oncologic outcomes compared with 
other surgical modalities. The role of robotic-assisted surgery is continuing to expand and new promising approaches 
with added benefits are emerging, such as the one of the ALF-X system. Surgeons await results from additional series of 
radical hysterectomy performed by robo-endoscopic assisted surgery and from International prospective randomized 
trial evaluating outcomes in patients randomly assigned to either open or laparoscopic/robotic radical hysterectomy. 
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